Integra LifeSciences Holdings Co. (NASDAQ:IART) Stock Holdings Trimmed by Nuveen Asset Management LLC

Nuveen Asset Management LLC lessened its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 26.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 184,375 shares of the life sciences company's stock after selling 67,698 shares during the quarter. Nuveen Asset Management LLC owned about 0.24% of Integra LifeSciences worth $4,182,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of IART. Quadrant Capital Group LLC boosted its holdings in shares of Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock worth $32,000 after purchasing an additional 1,371 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in shares of Integra LifeSciences by 821.7% during the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after purchasing an additional 1,931 shares during the last quarter. Covestor Ltd boosted its holdings in shares of Integra LifeSciences by 61.8% during the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock worth $123,000 after purchasing an additional 2,071 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of Integra LifeSciences during the fourth quarter worth $180,000. Finally, NorthRock Partners LLC acquired a new stake in shares of Integra LifeSciences during the fourth quarter worth $251,000. Institutional investors and hedge funds own 84.78% of the company's stock.

Analyst Upgrades and Downgrades

IART has been the topic of several analyst reports. JMP Securities decreased their price objective on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. JPMorgan Chase & Co. cut their target price on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Truist Financial cut their target price on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Wells Fargo & Company cut their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Finally, Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Four research analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $18.63.

Integra LifeSciences Stock Up 0.5%

NASDAQ:IART traded up $0.06 during mid-day trading on Wednesday, hitting $13.10. The company had a trading volume of 830,494 shares, compared to its average volume of 1,035,284. The business has a fifty day simple moving average of $15.50 and a 200-day simple moving average of $20.72. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 1 year low of $11.60 and a 1 year high of $32.66. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -145.54, a PEG ratio of 0.73 and a beta of 1.16.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $382.65 million during the quarter, compared to analysts' expectations of $381.17 million. During the same period last year, the business earned $0.55 earnings per share. The company's revenue for the quarter was up 3.7% compared to the same quarter last year. Equities analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.